Article

Monocular treatment trial for glaucoma might not be valid

Las Vegas-Should clinicians abandon the use of a monocular drug trial in patients with glaucoma, which has been the preferred practice pattern for primary open-angle glaucoma issued by the American Academy of Ophthalmology (AAO)?

Both sides of this issue were debated during a point-counterpoint session at the Glaucoma Subspecialty Day meeting. M. Bruce Shields, MD, presented the arguments in favor of continuing monocular drug trials, and Tony Realini, MD, offered various points discrediting this practice.

First assumption

"The first assumption is that fellow eyes exhibit symmetrical spontaneous IOP fluctuations," Dr. Realini explained. "There are historical diurnal curve data, as well as data we published in 2002, demonstrating that spontaneous IOP fluctuations between fellow eyes of ocular hypertensive and glaucoma patients are dissimilar a substantial proportion of the time."

Dr. Realini cited a report from 1964 that compared diurnal curve shapes between fellow eyes of glaucoma patients and found that 45% of the subjects had different IOP curves in their fellow eyes. Another report in 1993 noted similar findings in 33% of patients with ocular hypertension and 36% with glaucoma. In his own research published in Ophthalmology in 2002, Dr. Realini found asymmetric IOP fluctuations between fellow eyes in patients with and without glaucoma.

"There are not compelling data in the literature that I am aware of showing that IOPs in fellow eyes fluctuate symmetrically," Dr. Realini said. "I am not sure anyone has ever looked, because everyone has just accepted it as a given."

Dr. Shields, the Marvin L. Sears Professor and chairman emeritus, Department of Ophthalmology and Visual Science, Yale University School of Medicine, New Haven, CT, acknowledged the evidence that asymmetric IOP fluctuation is supported by various studies as reported in the literature. One study, published in Ophthalmology in 2005 by J.H. Liu, A.J. Sit, and R.N. Weinreb, found that 24-hour IOP profiles in the right and left eyes of healthy individuals in a sleep study were similar. After examining the single pairs of IOP readings in individuals, the two eyes exhibited asymmetric IOP fluctuations at times. So, it may be helpful to determine mean IOP after several IOP readings over a period of time, he said.

In an editorial published in Ophthalmology in 2004, J. Piltz-Seymour and H. Jampel suggested the utility of taking multiple IOP measurements at different times during the day for a monocular treatment trial.

"Starting a medication simultaneously in both eyes would not eliminate the problem of asymmetric IOP fluctuation," Dr. Shields emphasized. "It would only reduce the chances of assessing how the drug is actually working."

Second assumption

Another assumption pertaining to the monocular drug trial is that no contralateral crossover effect is seen with a topical IOP-lowering agent. This isn't true in the case of beta blockers, noted Dr. Realini. In 2000, a report published in the American Journal of Ophthalmology showed that in eyes treated with a beta blocker there was an average IOP lowering effect of –5.9 mm Hg and the contralateral untreated eye had an IOP lowering of –1.5 mm Hg in initial one-eyed trials in the ocular hypertension treatment study.

Dr. Realini noted that with prostaglandin analogue use, the contralateral crossover effect is unlikely to occur.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.